Clear.Labs

Here is a slightly uncomfortable fact about the modern food supply and, for that matter, the modern hospital: the test that tells you whether there is Salmonella in the chicken, or Listeria in the ice cream, or which variant of a virus is spreading through a county, is often run more or less by hand. A skilled technician grows a culture, extracts DNA, preps a library, loads a sequencer, and then hands the raw data to a bioinformatician who turns it into something a human can act on. It works. It is also slow, expensive, and gated behind expertise that most food plants and many labs simply do not have on staff.

Clear Labs, founded in 2014 in San Carlos, California by Sasan Amini and Mahni Ghorashi, made a specific bet about this. The two had come out of Illumina - the company that made DNA sequencing cheap - and they noticed that cheap sequencing had not made sequencing easy. The reagents got affordable; the workflow stayed artisanal. So instead of building a faster sequencer, they built a robot around one.

The product is called Clear Dx. It is, in the least glamorous and most useful description available, an automated next-generation sequencing platform: robotics, a sequencer, and bioinformatics software wrapped into one instrument. You load samples. It does library prep, sequencing setup, and analysis, and it hands back an interpreted result - not just "positive," but the pathogen's whole genome, which tells you the strain and, increasingly, whether it is resistant to your drugs. The hands-on time is measured in minutes. Up to twelve microbial isolates go through end to end in about twenty-seven hours.

That last sentence is the entire business, really. The novelty is not that Clear Labs can sequence a genome; lots of people can sequence a genome. The novelty is that it can do it without you needing to know how to sequence a genome. This is the boring, valuable kind of innovation - the kind that turns a specialized research project into a routine test somebody runs on a Tuesday.

Then 2020 happened, and Clear Labs got the kind of demonstration you cannot buy. A company built to sequence pathogens in food discovered that a virus is also a pathogen, and that public health labs desperately needed exactly the thing it made: automated whole genome sequencing, at volume, run by people who were not genomics specialists. Clear Labs adapted the platform to SARS-CoV-2, earned an FDA Emergency Use Authorization, and within a year its instrument was sitting in more than half of US public health laboratories. The food-safety startup had, almost accidentally, become critical infrastructure for the pandemic response.

What is interesting about that pivot is how little had to change. Same box, different specimen. The whole argument for the platform was that the biology of "read this organism's genome and tell me what it is" generalizes, and COVID proved it in the most public way imaginable. It is why the company now points the same core technology at tuberculosis drug resistance, at bacteria and fungi pulled from sterile clinical sites, and - through a 2025 collaboration with Pillar Biosciences - at oncology sequencing workflows. The market keeps expanding because the machine keeps being the same machine.

On the food side, the credential that matters is not a splashy launch but a regulator's stamp. Clear Labs' platform is AOAC-certified and was approved under the USDA's National Poultry Improvement Plan for Salmonella detection. Regulatory acceptance is the unsexy thing that converts a clever device into a standard operating procedure - it is what lets a plant manager choose sequencing without having to defend the choice.

Investors have found the pitch persuasive. Clear Labs has raised roughly $171 million across five rounds, from Khosla Ventures, GV, Menlo Ventures, Wing Venture Capital, and later Counterpoint Global (Morgan Stanley) and T. Rowe Price - the sort of crossover names that show up when a company starts looking less like a science experiment and more like a business. The most recent round, a $30 million Series D, closed in early 2025 as the company pushed further into the clinic.